IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Interleukin-6 (IL-6) is a pleiotropic cytokine with critical roles in inflammation, immunity, and tissue regeneration.
• IL-6 exerts diverse biological activities through distinct signaling pathways, including classic signaling, IL-6 trans-signaling, and cluster signaling.
• Dysregulation of IL-6 signaling is implicated in the pathogenesis of inflammatory diseases, autoimmune disorders, and cancer.

Purpose of the Study:

• To provide a comprehensive overview of the complex biology of IL-6 signaling pathways.
• To summarize the current clinical applications of anti-IL-6 and anti-IL-6 receptor (IL-6R) therapeutics.
• To highlight emerging therapeutic strategies targeting specific IL-6 signaling pathways, particularly trans-signaling.

Main Methods:

• Review of existing literature on IL-6 biology and therapeutic interventions.
• Analysis of clinical trial data and pre-clinical studies of IL-6-targeted agents.
• Discussion of the mechanisms underlying different IL-6 signaling modes.

Main Results:

• IL-6 classic signaling and IL-6 trans-signaling mediate distinct cellular responses, with trans-signaling often associated with pro-inflammatory effects.
• Cluster signaling is essential for the development of pathogenic Th17 cells.
• Antibodies targeting IL-6 or IL-6R are effective treatments for diseases like rheumatoid arthritis (RA).

Conclusions:

• Understanding the intricate IL-6 signaling network is crucial for developing targeted therapies.
• Selective inhibition of IL-6 trans-signaling represents a promising therapeutic avenue for inflammatory conditions.
• Novel therapeutic agents are under development to specifically modulate IL-6 activity, offering potential for improved treatment outcomes.